Progression-free survival was significantly greater in the nivolumab plus ipilimumab group compared to nivolumab alone. 2. Treatment-related adverse events were slightly higher in nivolumab plus ...

In this randomized clinical trial, the use of ketorolac in patients with Acute Type A Aortic Dissection (aTAAD), was not associated with a significant difference in efficacy or safety. However, it was ...